• Explore /
  • Poster
  • / Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).

Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Tae Won Kim

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Tae Won Kim , Anneli Elme , Joon Ho Park , Anghel Adrian Udrea , Nebojsa S. Manojlovic , Xuesong Guan , A. Scott Jung , Eduard Vrdoljak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01412957

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3561)

DOI

10.1200/JCO.2017.35.15_suppl.3561

Abstract #

3561

Poster Bd #

184

Abstract Disclosures

Similar Posters

First Author: K. Oliner

First Author: Tae Won Kim

First Author: Tae Won Kim

First Author: Scott D. Patterson